These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 32440182)

  • 1. Familial Partial Lipodystrophy (FPLD): Recent Insights.
    Bagias C; Xiarchou A; Bargiota A; Tigas S
    Diabetes Metab Syndr Obes; 2020; 13():1531-1544. PubMed ID: 32440182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial partial lipodystrophy syndromes.
    Fernández-Pombo A; Sánchez-Iglesias S; Cobelo-Gómez S; Hermida-Ameijeiras Á; Araújo-Vilar D
    Presse Med; 2021 Nov; 50(3):104071. PubMed ID: 34610417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.
    Araujo-Vilar D; Sánchez-Iglesias S; Guillín-Amarelle C; Castro A; Lage M; Pazos M; Rial JM; Blasco J; Guillén-Navarro E; Domingo-Jiménez R; del Campo MR; González-Méndez B; Casanueva FF
    Endocrine; 2015 May; 49(1):139-47. PubMed ID: 25367549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary disease of adipose tissue: When to think about and how to evaluate it in clinical practice?
    Vatier C; Vigouroux C; Mosbah H
    Ann Endocrinol (Paris); 2024 Jun; 85(3):190-194. PubMed ID: 38871502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases.
    Vatier C; Vantyghem MC; Storey C; Jéru I; Christin-Maitre S; Fève B; Lascols O; Beltrand J; Carel JC; Vigouroux C; Bismuth E
    Curr Med Res Opin; 2019 Mar; 35(3):543-552. PubMed ID: 30296183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study.
    Foss-Freitas MC; Akinci B; Neidert A; Bartlett VJ; Hurh E; Karwatowska-Prokopczuk E; Oral EA
    Lipids Health Dis; 2021 Dec; 20(1):174. PubMed ID: 34865644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leptin replacement therapy in the management of lipodystrophy syndromes.
    Vigouroux C; Mosbah H; Vatier C
    Ann Endocrinol (Paris); 2024 Jun; 85(3):201-204. PubMed ID: 38871500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy.
    Park JY; Javor ED; Cochran EK; DePaoli AM; Gorden P
    Metabolism; 2007 Apr; 56(4):508-16. PubMed ID: 17379009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipodystrophy for the Diabetologist-What to Look For.
    Patni N; Garg A
    Curr Diab Rep; 2022 Sep; 22(9):461-470. PubMed ID: 35821558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipodystrophy Syndromes.
    Hussain I; Garg A
    Endocrinol Metab Clin North Am; 2016 Dec; 45(4):783-797. PubMed ID: 27823605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Primary lipodystrophies].
    Capeau J; Magré J; Lascols O; Caron M; Béréziat V; Vigouroux C
    Ann Endocrinol (Paris); 2007 Feb; 68(1):10-20. PubMed ID: 17320032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial Partial Lipodystrophy-Literature Review and Report of a Novel Variant in
    Rutkowska L; Salachna D; Lewandowski K; Lewiński A; Gach A
    Diagnostics (Basel); 2022 Apr; 12(5):. PubMed ID: 35626278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies.
    Nolis T
    J Hum Genet; 2014 Jan; 59(1):16-23. PubMed ID: 24152769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical generalized lipoatrophy and severe insulin resistance due to a heterozygous LMNA p.T10I mutation.
    Mory PB; Crispim F; Kasamatsu T; Gabbay MA; Dib SA; Moisés RS
    Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1252-6. PubMed ID: 19169477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance.
    Lambadiari V; Kountouri A; Maratou E; Liatis S; Dimitriadis GD; Karpe F
    Front Endocrinol (Lausanne); 2021; 12():684182. PubMed ID: 34168618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type 1 familial partial lipodystrophy: understanding the Köbberling syndrome.
    Guillín-Amarelle C; Sánchez-Iglesias S; Castro-Pais A; Rodriguez-Cañete L; Ordóñez-Mayán L; Pazos M; González-Méndez B; Rodríguez-García S; Casanueva FF; Fernández-Marmiesse A; Araújo-Vilar D
    Endocrine; 2016 Nov; 54(2):411-421. PubMed ID: 27473102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
    Akinci G; Akinci B
    Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thematic review series: Adipocyte Biology. Lipodystrophies: windows on adipose biology and metabolism.
    Hegele RA; Joy TR; Al-Attar SA; Rutt BK
    J Lipid Res; 2007 Jul; 48(7):1433-44. PubMed ID: 17374881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipodystrophies in Children.
    Mainieri F; Chiarelli F
    Horm Res Paediatr; 2022; 95(4):305-320. PubMed ID: 35189617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of morbidity and mortality patterns in familial partial lipodystrophy patients: insights from a population study.
    Guidorizzi NR; Valerio CM; Viola LF; Veras VR; Fernandes VO; Lima GEDCP; Flor AC; Araújo JS; Gonçalves Muniz RB; Moreira RO; De Paula FJA; Zajdenverg L; Dantas JR; Godoy-Matos AF; Montenegro Júnior RM; Foss-Freitas MC
    Front Endocrinol (Lausanne); 2024; 15():1359211. PubMed ID: 38887266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.